Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large.
Minerva. Francesca F
Key Findings
- These drugs can improve health and lower medical costs, but long‑term safety is still unknown.
- Widespread use might worsen weight‑based bias and widen socioeconomic gaps.
- Strong regulation and ongoing monitoring are needed to balance benefits and risks.
Practical Outcomes
- For biohackers, the main takeaway is to be aware of the broader ethical and societal issues before adopting these drugs, and to watch for regulatory guidance rather than expecting new dosing tricks or performance boosts.
Summary
The paper talks about the moral questions around using weight‑loss drugs like Ozempic and Mounjaro, pointing out both the health perks and the possible social problems, but it doesn’t give any new tips on how to use them.
Abstract
This paper explores the ethical implications of emerging weight-loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications promise significant benefits, including improved individual health outcomes, reduced healthcare costs and, potentially, reduced environmental harms. However, their widespread adoption raises various concerns, such as unknown long-term side effects, the exacerbation of weight-based discrimination, and the reinforcement of socioeconomic disparities. The paper argues that, with robust regulatory frameworks in place, the potential benefits of these medications are likely to outweigh the risks. Nonetheless, ongoing monitoring of their effect on individuals and society at large remains essential.
Study Information
pubmed
2025
2025-12-07T00:00:00.000Z
10.1111/bioe.70068